Trials / Unknown
UnknownNCT02199444
Effect of Sevelamer on P-cresol Levels in CKD
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Federico II University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The accumulation of p-cresol, a product of the metabolism of aromatic aminoacid operated by resident intestinal bacteria increases the cardiovascular risk of chronic kidney disease (CKD) patients. Therefore, therapeutic strategies to reduce plasma p-cresol levels are highly demanded. It has been reported that the phosphate binder sevelamer sequesters p-cresol in vitro, while in vivo studies on dialysis patients showed controversial results. Aim of our study was to evaluate the effect of sevelamer on p-cresol levels in CKD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sevelamer | The dose of Sev was 2400 mg (800 mg three times a day) in all patients. |
| DRUG | Placebo |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-05-01
- First posted
- 2014-07-24
- Last updated
- 2015-02-18
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02199444. Inclusion in this directory is not an endorsement.